Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...

SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science ...

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

This was the stock's third consecutive day of losses.